About Nephros (OTCMKTS:NEPH)
Nephros, Inc., a commercial stage medical device and commercial product company, develops and sells liquid purification filters and hemodiafiltration (HDF) systems primarily in the United States. The company's ultrafilters are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from water borne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. It offers HDF systems for use in conjunction with a hemodialysis machine that enables nephrologists to provide HDF treatment to patients with end stage renal disease; and hemodiafilters for use as dialyzers in an hemodialysis treatment, as well as other disposables for use in the hemodiafiltration treatment process. The company was founded in 1997 and is headquartered in South Orange, New Jersey.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolOTCMKTS:NEPH
CUSIPN/A
Phone201-343-5202
Debt
Debt-to-Equity Ratio0.49%
Current Ratio2.03%
Quick Ratio1.67%
Price-To-Earnings
Trailing P/E Ratio-11.80
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$3.81 million
Price / Sales8.86
Cash FlowN/A
Price / CashN/A
Book Value$0.04 per share
Price / Book14.75
Profitability
EPS (Most Recent Fiscal Year)($0.05)
Net Income$-800,000.00
Net Margins-21.24%
Return on Equity-238.35%
Return on Assets-74.71%
Miscellaneous
Employees15
Outstanding Shares57,220,000
Nephros (OTCMKTS:NEPH) Frequently Asked Questions
What is Nephros' stock symbol?
Nephros trades on the OTCMKTS under the ticker symbol "NEPH."
How were Nephros' earnings last quarter?
Nephros (OTCMKTS:NEPH) released its quarterly earnings results on Monday, February, 26th. The company reported ($0.01) EPS for the quarter. The business earned $1.30 million during the quarter. Nephros had a negative net margin of 21.24% and a negative return on equity of 238.35%. View Nephros' Earnings History.
When is Nephros' next earnings date?
Who are some of Nephros' key competitors?
Some companies that are related to Nephros include Obalon Therapeutics (OBLN), Arch Therapeutics (ARTH), Presbia (LENS), Cellect Biotechnology (APOP), Interpace Diagnostics Gr (IDXG), AIT Therapeutics (AITB), Neovasc (NVCN), Cytori Therapeutics (CYTX), Valeritas (VLRX), InVivo Therapeutics (NVIV), Alliqua BioMedical (ALQA), Neurometrix (NURO), Amedica (AMDA), Avinger (AVGR), STRATA Skin Sciences (SSKN), TearLab (TEAR) and Lombard Medical Technologies (EVARF).
Who are Nephros' key executives?
Nephros' management team includes the folowing people:
- Mr. Daron G. Evans, Pres, CEO & Director (Age 44)
- Mr. Andrew Astor, Chief Financial Officer (Age 61)
- Ms. Joleen C. Turner, VP of Marketing and VP of Bus. Devel.
- Mr. Shane Sullivan, Director of North American Sales
- Ms. Monet Carnahan RN, BSN,CDN, Director of Dialysis Products
Has Nephros been receiving favorable news coverage?
Media headlines about NEPH stock have been trending somewhat positive on Thursday, Accern reports. Accern identifies negative and positive news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nephros earned a media sentiment score of 0.12 on Accern's scale. They also assigned press coverage about the company an impact score of 47.74 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Nephros' major shareholders?
Nephros' stock is owned by many different of retail and institutional investors. Top institutional shareholders include PESSIN NORMAN H (4.30%). Company insiders that own Nephros stock include Andrew Astor and Daron Evans. View Institutional Ownership Trends for Nephros.
How do I buy shares of Nephros?
Shares of NEPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nephros' stock price today?
One share of NEPH stock can currently be purchased for approximately $0.59.
How big of a company is Nephros?
Nephros has a market capitalization of $30.90 million and generates $3.81 million in revenue each year. The company earns $-800,000.00 in net income (profit) each year or ($0.05) on an earnings per share basis. Nephros employs 15 workers across the globe.
How can I contact Nephros?
Nephros' mailing address is 380 LACKAWANNA PLACE, SOUTH ORANGE NJ, 07079. The company can be reached via phone at 201-343-5202.
MarketBeat Community Rating for Nephros (NEPH)
MarketBeat's community ratings are surveys of what our community members think about Nephros and other stocks. Vote "Outperform" if you believe NEPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NEPH will underperform the S&P 500 over the long term. You may vote once every thirty days.
Nephros (OTCMKTS:NEPH) Analyst Ratings History
| Date | Brokerage | Action | Rating | Price Target | Details |
|---|
(Data available from 4/19/2016 forward)
Nephros (OTCMKTS:NEPH) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Nephros (OTCMKTS NEPH) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.00%
Nephros (OTCMKTS NEPH) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 4/10/2018 | Andrew Astor | CFO | Buy | 80,000 | $0.45 | $36,000.00 | |  |
| 4/10/2018 | Daron Evans | Insider | Buy | 79,000 | $0.45 | $35,550.00 | | |
| 3/9/2018 | Andrew Astor | CFO | Buy | 5,000 | $0.48 | $2,400.00 | | |
| 12/4/2017 | Andrew Astor | CFO | Buy | 18,333 | $0.50 | $9,166.50 | | |
| 9/6/2017 | Daron Evans | Insider | Buy | 29,580 | $0.24 | $7,099.20 | | |
| 8/28/2017 | Andrew Astor | CFO | Buy | 10,000 | $0.27 | $2,700.00 | 186,709 | |
| 8/22/2017 | Daron Evans | Insider | Buy | 4,000 | $0.25 | $1,000.00 | | |
| 8/11/2017 | Andrew Astor | CFO | Buy | 20,000 | $0.26 | $5,200.00 | 186,666 | |
| 8/11/2017 | Daron Evans | Insider | Buy | 70,000 | $0.26 | $18,200.00 | | |
| 6/9/2017 | Daron Evans | Insider | Buy | 21,461 | $0.26 | $5,579.86 | | |
| 5/19/2017 | Daron Evans | Insider | Buy | 30,000 | $0.26 | $7,800.00 | | |
| 12/7/2016 | Daron Evans | Insider | Buy | 4,069 | $0.32 | $1,302.08 | 339,428 | |
| 12/5/2016 | Daron Evans | Insider | Buy | 10,620 | $0.34 | $3,610.80 | 329,339 | |
| 12/1/2016 | Daron Evans | Insider | Buy | 41,530 | $0.32 | $13,289.60 | 284,140 | |
| 8/31/2015 | Daron Evans | CEO | Buy | 44,175 | $0.57 | $25,179.75 | 169,759 | |
| 8/20/2015 | Daron Evans | CEO | Buy | 51,500 | $0.53 | $27,295.00 | 125,584 | |
(Data available from 1/1/2013 forward)
Nephros (OTCMKTS NEPH) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Rounds Report: Nephros To Profit From Industry Tailwinds While Improving FDA Policy To Benefit Patients And Investors
seekingalpha.com - April 19 at 3:52 PM |
 | Insider Buying: Nephros, Inc. (NEPH) Insider Purchases 79,000 Shares of Stock
www.americanbankingnews.com - April 12 at 7:35 PM |
| Nephros, Inc. (NEPH) CFO Andrew Astor Buys 80,000 Shares
www.americanbankingnews.com - April 12 at 7:35 PM |
| Nephros announces $2.9M private placement
seekingalpha.com - April 11 at 11:01 AM |
 | Nephros Announces $2.9 Million Private Placement
finance.yahoo.com - April 11 at 11:01 AM |
 | Form 424B3 NEPHROS INC
www.streetinsider.com - April 5 at 3:45 PM |
| Nephros, Inc. to Post FY2018 Earnings of ($0.02) Per Share, Seethru Equity Forecasts (NEPH)
www.americanbankingnews.com - March 8 at 9:08 AM |
| SeeThruEquity Issues Update on Nephros (NEPH) with Target Price of $1.80
finance.yahoo.com - March 5 at 11:03 AM |
| Nephros to Present at NobleCon14
finance.yahoo.com - January 23 at 9:07 AM |
| Nephros Announces Preliminary Financial Results for Fourth Quarter 2017
finance.yahoo.com - January 4 at 9:47 AM |
| Nephros Receives $1.8 Million in Cash from Sale of Tax Credits
finance.yahoo.com - December 13 at 10:08 AM |
| Nephros CFO to Present at the 10th Annual LD Micro Main Event
finance.yahoo.com - December 4 at 9:50 AM |
| ValuEngine Downgrades Nephros (NEPH) to Sell
www.americanbankingnews.com - December 3 at 12:40 AM |
| Nephros, Inc. :NEPH-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 9:57 AM |
| Nephros Inc. (NEPH) Expected to Post FY2017 Earnings of ($0.05) Per Share
www.americanbankingnews.com - November 17 at 8:30 PM |
| SeeThruEquity Issues Update on Nephros, Inc. (NEPH)
finance.yahoo.com - November 15 at 6:41 AM |
Nephros (OTCMKTS:NEPH) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Nephros (OTCMKTS NEPH) Stock Chart for Thursday, April, 19, 2018
Loading chart…
